CANCER CHRONOMICS II Origins of timing cancer treatment

Por Cornélissen, Germaine, Berezkin, Mikhail Victorovich, Syutkina, Elena V., Blank, Mikhail A, Blank, Olga A, Chibisov, Sergei M., Halberg, Franz
Publicado em 2006

An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias

Por Barretto, Nisha N., Karahalios, Dean S., You, Dewen, Hemenway, Charles S.
Publicado no J Exp Ther Oncol (2014)

Schedule shifts, cancer and longevity: good, bad or indifferent?

Por Cornélissen, Germaine, Halberg, Julia, Halberg, Franz, de la Pena, Salvador Sanchez, Nelson, Walter, Schwartzkopff, Othild, Stoynev, Alexander, Haus, Erhard
Publicado em 2008

CANCER CHRONOMICS III: Chronomics for cancer, aging, melatonin and experimental therapeutics researchers

Por Halberg, Franz, Cornélissen, Germaine, Ulmer, Waldemar, Blank, Mikhail, Hrushesky, William, Wood, Patricia, Singh, Rajesh K, Wang, Zhengrong
Publicado em 2006

Anticancer agent xanthohumol inhibits IL-2 induced signaling pathways involved in T cell proliferation

Por Liu, Yongbo, Gao, Xiaohua, Deeb, Dorrah, Arbab, Ali S., Dulchavsky, Scott A., Gautam, Subhash C.
Publicado em 2012

A new paradigm for the development of anticancer agents from natural products

Por Subramanian, Balanehru, Nakeff, Alexander, Tenney, Karen, Crews, Phillip, Gunatilaka, Leslie, Valeriote, Fred
Publicado em 2006

Origins of timed cancer treatment: early marker rhythm-guided individualized chronochemotherapy

Por Halberg, Franz, Prem, Konald, Halberg, Francine, Norman, Catherine, Cornélissen, Germaine
Publicado em 2006

Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells

Por Jiang, Hao, Shang, Xia, Wu, Hongtao, Gautam, Subhash C., Al-Holou, Shaza, Li, Christina, Kuo, Jarret, Zhang, Lijie, Chopp, Michael
Publicado em 2009

Role of reactive oxygen species (ROS) in CDDO-Me-mediated growth inhibition and apoptosis in colorectal cancer cells

Por Gao, Xiaohua, Deeb, Dorrah, Liu, Patricia, Liu, Yongbo, Arbab-Ali, Syed, Dulchavsky, Scott A., Gautam, Subhash C.
Publicado em 2011

A PHOSPHOPEPTIDE MIMETIC PRODRUG TARGETING THE SH2 DOMAIN OF STAT3 INHIBITS TUMOR GROWTH AND ANGIOGENESIS

Por Auzenne, Edmond J., Klostergaard, Jim, Mandal, Pijus K., Liao, Warren S., Lu, Zhen, Gao, Fengqin, Bast, Robert C., Robertson, Fredika M., McMurray, John S.
Publicado em 2012

Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR Signaling

Por Gao, Xiaohua, Liu, Yongbo, Deeb, Dorrah, Arbab, Ali S., Gautam, Subhash C.
Publicado no J Exp Ther Oncol (2014)

VEGF(165) is necessary to the metastatic potential of Fas(−) osteosarcoma cells but will not rescue the Fas(+) cells.

Por Jia, Shu-Fang, Guan, Hui, Duan, Xiaoping, Kleinerman, Eugenie S.
Publicado em 2008

Clinicopathological predictors of lymphatic metastasis in HNSCC: implications for molecular mechanisms of metastatic disease

Por Goldson, Tovë M., Han, Yimei, Knight, Kristen B., Weiss, Heidi L., Resto, Vicente A.
Publicado em 2010

Angiotensin receptor signaling and prostate tumor growth in mice

Por Scott-Emuakpor, Jem, Allot, Emma, Johnson, Stacy A., Howard, Lauren E., Macias, Everardo, Freedland, Stephen J., Gurley, Susan B.
Publicado no J Exp Ther Oncol (2017)

Inhibition of BCL2 expression and activity increases H460 sensitivity to the growth inhibitory effects of polyphenon E()

Por Borgovan, Theodor, Bellistri, John-Paul S., Slack, Kristen N., Kopelovich, Levy, Desai, Manisha, Joe, Andrew K.
Publicado no J Exp Ther Oncol (2009)

Inhibition of cell proliferation and induction of apoptosis by CDDO-Me in pancreatic cancer cells is ROS-dependent

Por Deeb, Dorrah, Gao, Xiaohua, Liu, Yong Bo, Gautam, Subhash C.
Publicado em 2012